RMD.AX - ResMed Inc.
| Previous close | 33.25 |
| Open | 33.49 |
| Bid | 33.25 x 51100 |
| Ask | 33.26 x 25600 |
| Day's range | 33.17 - 33.56 |
| 52-week range | 27.83 - 36.37 |
| Volume | |
| Avg. volume | 1,012,180 |
| Market cap | 49.304B |
| Beta (5Y monthly) | 0.48 |
| PE ratio (TTM) | 37.80 |
| EPS (TTM) | 0.88 |
| Earnings date | N/A |
| Forward dividend & yield | 0.26 (0.80%) |
| Ex-dividend date | 10 May 2023 |
| 1y target est | 36.55 |
GlobeNewswireResMed Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023, beginning at approximately 9:20 a.m. (Pacific Daylight Time) at the Waldorf Astoria Monarch Beach in Dana Point, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting http
ZacksZBH vs. RMD: Which Stock Should Value Investors Buy Now?
ZBH vs. RMD: Which Stock Is the Better Value Option?
- GlobeNewswire
3 World-Renowned Sleep Apnea Experts Present New Benefits of PAP Therapies at ATS 2023
France’s Jean-Louis Pépin and Germany’s Holger Woehrle presented studies in which treating OSA with CPAP lowered all-cause mortality for PAP vs. non-PAP users with OSAGermany’s Michael Arzt presented new evidence that treating CSA with ASV* caused “a significant and clinically relevant improvement in disease-specific QoL, daytime sleepiness, and quality of sleep” WASHINGTON, May 25, 2023 (GLOBE NEWSWIRE) -- Renowned medical experts at the American Thoracic Society International Conference unveil
Simply Wall St.ResMed Inc. (NYSE:RMD) is favoured by institutional owners who hold 74% of the company
Key Insights Given the large stake in the stock by institutions, ResMed's stock price might be vulnerable to their...
- Simply Wall St.
With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
- GlobeNewswire
ResMed Appoints Michael Rider its Next Global General Counsel, Dawn Haake its First Chief Quality Officer
Rider and Haake, both internal promotions, joined ResMed’s executive team on May 1Rider, currently Senior Vice President, Deputy Global General Counsel will succeed retiring Chief Administrative Officer, Global General Counsel, and Secretary David Pendarvis on July 1 SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced the appointment of two new executive team members: Michael Rider, Global General Counsel & Secretary, effective July 1, 2023, and Dawn Haake as
ZacksResMed (RMD) Q3 Earnings and Revenues Surpass Estimates
ResMed (RMD) reports a solid third-quarter top line, led by strong device sales growth through steady production and delivery of its cloud-connected flow generator devices to meet high market demand.
ZacksResMed (RMD) Q3 Earnings and Revenues Beat Estimates
ResMed (RMD) delivered earnings and revenue surprises of 7.01% and 7.95%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2023
Year-over-year revenue grows 29%, operating profit up 28%, non-GAAP operating profit up 27%Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2023. Third Quarter 2023 HighlightsAll comparisons are to the prior year period Revenue increased by 29% to $1,116.9 million; up 31% on a constant currency bas
- GlobeNewswire
ResMed to Report Third Quarter Fiscal 2023 Earnings on April 27, 2023
SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2023 on Thursday, April 27, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: •Location:http://investor.resmed.com•Date:
- Simply Wall St.
ResMed Inc.'s (NYSE:RMD) Stock Been Rising: Are Strong Financials Guiding The Market?
ResMed's (NYSE:RMD) stock up by 7.8% over the past three months. Given that the market rewards strong financials in the...
- GlobeNewswire
ResMed Chief Administrative Officer and Global General Counsel to Retire
ResMed to conduct an internal search for a successor general counselAmy Wakeham appointed Chief Communications and Investor Relations Officer, will join ResMed’s executive leadership team SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) announced today that David Pendarvis, chief administrative officer, global general counsel, and secretary, plans to retire, effective June 30, 2023. He will remain in a consulting role with ResMed through December 31, 2023. ResMed will c
Motley Fool3 Incredible Growth Stocks to Buy Right Now
U.S. stock markets are going through an unusually volatile period, thanks to the uncertainty posed by the global banking crisis and the Federal Reserve's plan for interest rates. While wild price swings can be nerve-racking for shareholders, choppy markets can also be a great time to pick up shares of top companies at significant discounts to their intrinsic value. Which growth stocks are on watch for a possible entry point?
ZacksReasons Why You Should Retain ResMed (RMD) Stock For Now
Investors are optimistic about ResMed's (RMD) Increased demand for its digital health solution.
- GlobeNewswire
ResMed Announces Participation in the 2023 KeyBanc Life Sciences & MedTech Investor Forum
SAN DIEGO, March 15, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will join a fireside chat at the 2023 KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, beginning at approximately 3:45 p.m. (Eastern Daylight Time) via webcast. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The audio-only webcast repla
- GlobeNewswire
ResMed’s Annual Global Sleep Survey Finds 8 in 10 Adults Experience Signs of Disruption Related to Their Quality of Sleep
81% of respondents experience one or more symptoms indicating poor sleep quality, despite 64% saying they’re satisfied with the quantity of their sleepWomen and older generations are less satisfied with the quality and quantity of their sleep compared to the survey’s overall average Annual survey aims to raise awareness for sleep health during National Sleep Awareness Week and World Sleep Day SAN DIEGO, March 13, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) announced today the results f
ZacksEYE vs. RMD: Which Stock Should Value Investors Buy Now?
EYE vs. RMD: Which Stock Is the Better Value Option?
- GlobeNewswire
ResMed Announces Participation in the Oppenheimer 33rd Annual Healthcare Conference
SAN DIEGO, March 07, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, beginning at approximately 11:20 a.m. (Eastern Daylight Time) via webcast. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The audio-only webcast replay will be available
- Simply Wall St.
Is ResMed Inc. (NYSE:RMD) Worth US$216 Based On Its Intrinsic Value?
Key Insights ResMed's estimated fair value is US$178 based on 2 Stage Free Cash Flow to Equity ResMed is estimated to...
ZacksTop Research Reports for Chevron, Novo Nordisk & Amgen
Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), Novo Nordisk A/S (NVO) and Amgen Inc. (AMGN).
- Zacks
ResMed's (RMD) Mask Sales Drive Growth, Margin Issue Lingers
ResMed (RMD) continues to see robust demand for its market-leading mask portfolio despite being faced with challenges related to lower new patient setups from a competitor recall.
- Simply Wall St.
ResMed Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS In Line
ResMed ( NYSE:RMD ) Second Quarter 2023 Results Key Financial Results Revenue: US$1.03b (up 16% from 2Q 2022). Net...
ZacksESLOY vs. RMD: Which Stock Is the Better Value Option?
ESLOY vs. RMD: Which Stock Is the Better Value Option?
ZacksResMed's (RMD) Q2 Earnings Beat Estimates, Margins Falls
ResMed's (RMD) mask sales growth was strong across the globe, reflecting a post-COVID pandemic awareness about the importance and need for respiratory hygiene and respiratory health.
ZacksResMed (RMD) Q2 Earnings and Revenues Surpass Estimates
ResMed (RMD) delivered earnings and revenue surprises of 3.75% and 3.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
